key: cord-0797141-h2mrvp1t
authors: Severa, Martina; Diotti, Roberta A.; Etna, Marilena P.; Rizzo, Fabiana; Fiore, Stefano; Ricci, Daniela; Iannetta, Marco; Sinigaglia, Alessandro; Lodi, Alessandra; Mancini, Nicasio; Criscuolo, Elena; Clementi, Massimo; Andreoni, Massimo; Balducci, Stefano; Barzon, Luisa; Stefanelli, Paola; Clementi, Nicola; Coccia, Eliana M.
title: Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
date: 2021-04-19
journal: bioRxiv
DOI: 10.1101/2021.04.17.440278
sha: b42d93786706863daec8be6f861b5c22ee5f67ae
doc_id: 797141
cord_uid: h2mrvp1t

SARS-CoV-2 fine-tunes the interferon (IFN)-induced antiviral responses, which play a key role in preventing coronavirus disease 2019 (COVID-19) progression. Indeed, critically ill patients show an impaired type I IFN response accompanied by elevated inflammatory cytokine and chemokine levels, responsible for cell and tissue damage and associated multi-organ failure. Here, the early interaction between SARS-CoV-2 and immune cells was investigated by interrogating an in vitro human peripheral blood mononuclear cell (PBMC)-based experimental model. We found that, even in absence of a productive viral replication, the virus mediates a vigorous TLR7/8-dependent production of both type I and III IFNs and inflammatory cytokines and chemokines, known to contribute to the cytokine storm observed in COVID-19. Interestingly, we observed how virus-induced type I IFN secreted by PBMC enhances anti-viral response in infected lung epithelial cells, thus, inhibiting viral replication. This type I IFN was released by plasmacytoid dendritic cells (pDC) via an ACE-2-indipendent mechanism. Viral sensing regulates pDC phenotype by inducing cell surface expression of PD-L1 marker, a feature of type I IFN producing cells. Coherently to what observed in vitro, asymptomatic SARS-CoV-2 infected subjects displayed a similar pDC phenotype associated to a very high serum type I IFN level and induction of anti-viral IFN-stimulated genes in PBMC. Conversely, hospitalized patients with severe COVID-19 display very low frequency of circulating pDC with an inflammatory phenotype and high levels of chemokines and pro-inflammatory cytokines in serum. This study further shed light on the early events resulting from the interaction between SARS-CoV-2 and immune cells occurring in vitro and confirmed ex vivo. These observations can improve our understanding on the contribution of pDC/type I IFN axis in the regulation of the anti-viral state in asymptomatic and severe COVID-19 patients. Author summary SARS-CoV-2 pandemic has resulted in millions of infections and deaths worldwide, yet the role of host innate immune responses in COVID-19 pathogenesis remains only partially characterized. Innate immunity represents the first line of host defense against viruses. Upon viral recognition, the secretion of type I and III interferons (IFN) establishes the cellular state of viral resistance, and contributes to induce the specific adaptive immune responses. Moving from in vitro evidences on the protective role played by plasmacytoid dendritic cells (pDC)-released type I IFN in the early phase of SARS-CoV-2 infection, here we characterized ex vivo the pDC phenotype and the balance between anti-viral and pro-inflammatory cytokines of COVID-19 patients stratified according to disease severity. Our study confirms in COVID-19 the crucial and protective role of pDC/type I IFN axis, whose deeper understanding may contribute to the development of novel pharmacological strategies and/or host-directed therapies aimed at boosting pDC response since the early phases of SARS-CoV-2 infection.

INTRODUCTION particular, nsp13, nsp14, nsp15, ORF6, ORF8, ORF3b and nucleocapsid proteins act as competent 92 suppressors of IFN-β; while nsp1, nsp12, nsp13, nsp15 and the M protein are also potent inhibitors 93 of the MAVS pathway (14) (15) (16) . 94

In this paper, we investigate the SARS-CoV-2-elicited innate immune response using a human 95 PBMC-based in vitro experimental model. We evaluate the key role of plasmacytoid dendritic cells 96 (pDC) in the induction of type I IFN response in this context. Also, we performed an in-depth 97 analysis of pDC phenotype and IFN and cytokine levels in COVID-19 patients, stratified according 98 to disease severity, to evaluate possible correlation with COVID-19 progression and subsequent 99 life-threatening complications. 100 expression, mirroring a strong reduction of type I IFN production and, thus, confirming what 153 already observed (7, 12) (Fig 5A) . 154 Importantly, we first demonstrated that treatment of Calu-3 cells with supernatants collected from 155 SARS-CoV-2-stimulated human PBMC (sup PBMC_CoV2) strongly induced the transcription of 156 the IFN-inducible gene Mx1, differently to what observed in cultures treated with supernatant from 157 not stimulated PBMC (sup PBMC_ns) (Fig 5A) . 158

To understand if type I IFN naturally released by infected PBMC can inhibit SARS-CoV-2 159 replication, we infected Calu-3 cells conditioned with either sup PBMC_ns or sup PBMC_CoV2 160 (Fig 5B and 5C ). In our experimental setting, while addition of sup PBMC_ns affected neither Mx1 161 transcription nor SARS-CoV-2 replication, presence of sup PBMC_CoV2 correlated to an enhanced 162 ISG signature and combined inhibition of SARS-CoV-2 infection as revealed by viral titrations of 163 supernatants from Calu-3 cells (Fig 5B and 5C) . in SARS-CoV-2-stimulated PBMC, we hypothesized that pDC could be the main cell type 171 responsible for type I IFN production. In addition, we also tested the possibility that the TLR8-172 expressing resting CD14 + monocytes would be involved. 173

Thus, pDC were purified from PBMC of healthy donors and stimulated for 24 hours with SARS-174

CoV-2 (0.1 MOI) (Fig 6) . In pDC cultures a strong production of comparable to what 175 found in PBMC, was detected, and this was clearly dependent on TLR7 signaling since I-TLR7/8 176 blocked release of this cytokine (Fig 6A) . SARS-CoV-2 stimulation of pDC did not depend on 177 ACE-2 mediated viral entry or on the transmembrane serine protease 2 (TMPRSS2), both not 178 expressed by these cells in baseline condition or after stimulation with IFN-αs and IFN-β (S2A 179 pDC undergo phenotypical diversification in response to viral infections or single stimuli through 188 environmental plasticity (22). They can diversify into three stable populations: P1-pDC (PD-189 L1 + CD80 -) specialized for type I IFN production, P2-pDC (PD-L1 + CD80 + ) displaying both innate 190 and adaptive functions and P3-pDC (PD-L1 -CD80 + ) specifically with adaptive functions (22). In 191 our experimental setting we monitored pDC phenotype and found a clear-cut increase of the 192 frequency of PD-L1 + P1-pDC, in accordance with the detected high IFN-α release, upon CoV-2 stimulation (Fig 6B) . In line with these data, SARS-CoV-2-treated total pDC and P1-pDC 194 display a very high surface expression of PD-L1 (Fig 6C) . In presence of the TLR-7/8 inhibitor, P1 195 phenotype upon SARS-CoV-2 stimulation reverted into the more adaptive P2 and P3 populations, 196 similarly to R848-treated cultures (Fig 6B) , with a strong increase of the surface level of CD80 (Fig 197 6C) . Accordingly, along with the maturation process, exemplified by the induction of the co-198 stimulatory marker CD86 (Fig 6C) , SARS-CoV-2-treated pDC turn from type I and IL-6-producing cells in the presence of the TLR-7/8 inhibitor (Fig 6D) . We first monitored whether the degree of COVID-19 severity would match to a differential level of 208 circulating pDC and found a striking difference in the three analyzed groups (Fig 7A) . The 209 frequency as well as the absolute number of pDC were reduced in asymptomatic SARS-CoV2 210 infected subjects as compared to HD (Fig 7A) . According to the observed lymphopenia (S2 Table) , 211 symptomatic hospitalized patients had a very and consistently low level/depletion of circulating 212 pDC independently of their age and sex (Fig 7A) . 213

Further analysis of pDC phenotype in these groups highlighted that CP-AS mainly display a PD-214 L1 + P1 phenotype; while, on the contrary, in CP mainly PD-L1 + CD80 + P2-pDC were observed (Fig 215 7B and 7C). These data were in accordance also to the surface level of both PD-L1 and CD80 216 markers in pDC expressed in terms of mean fluorescence intensity (MFI) (Fig 7D and S3B Fig) . 217 Importantly, CD86, which was significantly expressed in CP pDC, was further enhanced in CP-AS 218

indicating that asymptomatic infection with SARS-CoV-2 strongly activates pDC (Fig 7D and S3B 219 Fig) . 220

We then monitored the expression of CXCR3 and CXCR4 on pDC, responsible for their 221 localization to infected peripheral tissues including skin and epithelia, as well as of CCR7 and 222 CD62-L, a chemokine receptor and an integrin that promote pDC lymph node homing respectively 223 (Fig 7E and 7F) . SARS-CoV-2 natural infection significantly increased both frequency (Fig 7E) 

To investigate if the significant difference in number and activation status observed in pDC of 232 asymptomatic and severe COVID-19 patients would mirror a different anti-viral state in these 233 individuals, we analyzed in ex vivo PBMC derived from HD, CP-AS and CP the transcription of the 234 classical ISG, Mx1, and found a striking difference in its expression level (Fig 8A) . RNA from CP-235 AS PBMC displayed a very high level of this gene as compared to HD, while CP PBMC had a 236 much lower expression, even if significantly higher than HD cells (Fig 8A) . Interestingly and in 237 accordance with these results, IFN-α level markedly raised in sera of CP-AS as compared to CP 238 and HD (Fig 8B) . 239

The pro-inflammatory cytokines IL-6, TNF-α and IL-1β (Fig 8C) together with the chemotactic 240 factors CXCL-10, CCL-2 and CXCL-8 (Fig 8D) had a specular profile to that observed for Indeed, they were all found more increased in sera of critical than in asymptomatic COVID-19 242 subjects (Fig 8C and 8D ). Interestingly, the serum level of IL-10, a regulatory cytokine with a 243 strong anti-inflammatory potential also known to be induced by type I IFN, was significantly 244 increased also in CP-AS (Fig 8C) . Similarly, serum CXCL-10, whose transcription is mainly 245 regulated by type II IFN-γ-mediated signaling but in part also by type I IFNs, was enhanced not 246 only in CP but partly also in CP-AS (Fig 8D) . with an altered induction of type I and III IFNs associated with a high release of chemokines (12, 257 25) . Accordingly, in vivo data from severely ill SARS-CoV-2-infected patients confirmed an 258 impaired type I IFN response accompanied by elevated pro-inflammatory cytokine levels in sera (7, 259 12), thus identifying exacerbated and abnormal responses in the innate branch of the immune 260 system as a main driver of major illness (25). 261

In the present study, we interrogated human PBMC, a mixture of highly specialized immune cells, 262 to understand their contribution to COVID-19 immunopathogenesis and the dynamic interaction 263 between immune system and SARS-CoV-2 virus. We showed that human PBMC, even if not 264 allowing a productive viral replication, respond to stimulation with a SARS-CoV-2 clinical isolate 265 by expressing high levels of type I and III IFNs and a concomitant ISG transcription, as well as of 266 the inflammatory cytokines IL-6, TNF-α and IL-1β. 267

It is well known that lymphopenia, together with neutrophilia and monocytopenia, is a characteristic 268 of patients with severe . Consistently with these data, one of the main mechanisms 269 associated with disease severity is the recruitment of inflammatory immune cells towards infected 270 lungs and the subsequent hyperinflammatory state or the so-called cytokine releasing syndrome, 271 which includes inflammatory mediators as well as chemokines (6, 27 Type I IFNs emerged as key protective factors in preventing COVID-19 disease severity. Genetical 301 analyses of COVID-19 patients with life-threatening pneumonia had, indeed, reported inborn errors 302 of type I IFN immunity and variants in genes encoding for RNA sensors and type I IFN regulating 303 elements in absence of other risk factors (39, 40). Furthermore, more than 10% of COVID-19 304 patients with severe pneumonia had neutralizing auto-antibodies against either type I IFN-ϖ or IFN-305 αs, or both, before disease onset and 94% of them were males; findings that might also explain the 306 excess of men among the individuals with life-threatening COVID-19 disease (41) . Moreover, 307

severe COVID-19 patients uniquely produce antibodies that functionally block, through binding of 308 the Fc domain to FcγR-IIb, the production of type I IFN and ISG-expressing cells found in mild 309 disease (25). 310

Having in mind all these evidences, we investigated which immune cell type is responsible for type 311 I IFN release upon SARS-CoV-2 stimulation. pDC are known to be the principal cell type among 312 immune cells specialized in type I IFN release sensing viral RNA in a TLR7-dependent manner 313 (19) . pDC can sense almost all viruses, including the coronaviruses SARS-CoV and Middle East 314 respiratory syndrome coronavirus (MERS) (42-44), and were shown to recognize MERS via TLR7 315 (44). In our study, pDC isolated from peripheral blood of healthy donors and stimulated in vitro 316 with SARS-CoV-2 produced a high amount of TLR7-mediated IFN-αs, with a level comparable to 317 that found in PBMC cultures, even if pDC do not express both the entry factors ACE-2 or 318 TMPRSS2 [our data and (45)]. 319

Further, our study showed that stimulation with SARS-CoV-2 regulated pDC phenotype and 320 activation status. Hence, viral sensing mediates the cell surface up-regulation of PD-L1 on more of 321 the 55% of cultured pDC, a phenotype found in pDC specialized in type I IFN production (22). In 322 presence of a TLR-7/8 inhibitor SARS-CoV-2-treated pDC turn from PD-L1 + CD80to PD-323 L1 + CD80 + or CD80 + only expressing cells, two subpopulations known to mediate adaptive 324 functions and T cell interaction (22), as exemplified in our study also by the up-regulation of the 325 costimulatory and maturation-associated marker CD86. Accordingly, pDC in presence of SARS-326

CoV-2 and TLR7/8 inhibitor do not release type I IFNs and turn into TNF-α-and IL-6-producing 327 cells. Production of the pro-inflammatory cytokine TNF-α, in particular, is known to negatively 328 control in a autocrine/paracrine fashion the production of IFN-αs in pDC as soon as the maturation 329 process starts (46). While we were finalizing this paper, Onodi and colleagues published similar 330 results showing that SARS-CoV-2, in absence of productive infection, induces pDC phenotype 331 diversification at a level similar to influenza virus (45). SARS-CoV-2-mediated type I IFN 332 production was then blocked in pDC by hydroxychloroquine (45) (47). In particular, pDC have been 336 extensively studied in patients with severe COVID-19 and were found significantly reduced or 337 absent in the blood of these individuals (47-49). Importantly, while inflammatory monocytes and 338

CD1c + conventional DC were present in lung infiltrates of patients with severe COVID-19, 339 CD123 hi pDC were depleted in blood but absent in the lungs (50). 340

While Onodi et al. demonstrated in vitro that pDC activation by SARS-CoV-2 is dependent on 341 IRAK4-and UNC93B1-mediated signaling pathways by means of patients genetically deficient in 342 genes encoding these factors (45), in this study we deepen the current understanding on pDC 343 contribution and phenotype diversification in SARS-CoV-2 infection by characterizing ex vivo 344 blood samples derived from patients at different COVID-19 disease severity. As expected, we 345 observed a profound pDC depletion, in terms of both frequency and absolute numbers, in patients 346 hospitalized with severe COVID-19 as compared to matched HD. Interestingly, then, in a cohort of 347 asymptomatic SARS-CoV-2-infected individuals circulating pDC were already reduced in the 348 peripheral blood as respect to the healthy counterpart but significantly higher than what found in 349 hospitalized COVID-19 patients. Nonetheless, the phenotype was drastically different in pDC 350 derived from severely infected or asymptomatic subjects. pDC from asymptomatic COVID-19 351 mainly expressed PD-L1, while cells derived from severe COVID-19 were consistently represented 352 by PD-L1 + CD80 + phenotype. Importantly, the analysis of costimulatory marker CD86, that was 353 significantly expressed in pDC from critically ill patients and further enhanced in cells of 354 asymptomatic subjects, indicated that pDC are strongly activated during asymptomatic infection. 355

We also observed that the expression of chemokine receptors responsible for pDC localization to 356 infected peripheral tissues, such as CXCR3 and CXCR4, or for their lymph node homing, as CCR7 T  h  e  a  u  t  h  o  r  s  a  c  k  n  o  w  l  e  d  g  e  D  r  .  V  a  l  e  n  t  i  n  a  T  i  r  e  l  l  i  a  n  d  D  r  .  M  a  s  s  i  m  o  S  a  n  c  h  e  z  o  f  F  l  o  w  C  y  t  o  m  e  t  r  y   494   F  a  c  i  l  i  t  y  (  F  A  S  T  ,  I  s  t  i  t  u  t  o  S  u  p  e  r  i  o  r  e  d  i  S  a  n  i 

Auto-612 antibodies against type I IFNs in patients with life-threatening COVID-19

Control of 614 coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the 618 Middle East respiratory syndrome coronavirus

High 620 secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East 621 respiratory syndrome coronavirus

SARS-CoV-2 623 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4

Cross-regulation of TNF and 626 IFN-alpha in autoimmune diseases

Acute SARS-CoV-2 Infection 628 Impairs Dendritic Cell and T Cell Responses

A dynamic 630 COVID-19 immune signature includes associations with poor prognosis

Increased 633 sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood

Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 635 Pneumonia

COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and 638 inflammatory transitional and nonclassical monocytes

COVID-19: 640 consider cytokine storm syndromes and immunosuppression

Cytokine storm and COVID-19: a chronicle of 642 pro-inflammatory cytokines

A cell 644 type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked 645 pathogenic signatures in Multiple Sclerosis

EBV 647 stimulates TLR-and autophagy-dependent pathways and impairs maturation in plasmacytoid 648 dendritic cells: implications for viral immune escape

MOI) in presence of 24 hour-supernatants collected from either ns PBMC cultures

grey dotted bars) or from SARS-CoV-2 (MOI=0.02)-treated PBMC cultures

Mx1 gene expression was quantified by real time PCR and 705 quantification data normalized to TBP level by using the equation 2 -ΔCt . (C) Virus titers were 706 evaluated in supernatants from infected Calu-3 cultures described in (B) by Endpoint Dilution 707 Assay by using the Reed-Muench formula and reported as TCID 50 /ml

Shown results were mean relative values ± SEM of 3 independent experiments. P-values were 709 depicted as follows: *p≤0

Purified plasmacytoid dendritic cells (pDC) were left 713 untreated (not stimulated, ns) or stimulated for 24 hours with the TLR7/8 agonist R848 (5µM) as 714 positive control, with SARS-CoV-2 (CoV2; MOI=0.1) in presence or absence of a 30 minute pre-715 treatment with a specific TLR7/8 inhibitor (I-TLR7/8, 1µM), or with Mock medium only

Representative dot plot profile out 721 of 3 different experiments independently conducted is shown. (C) Surface expression of CD86

Production of TNF-α and IL-6 was tested by cytometric bead assay in 24 hour-collected pDC 724 culture supernatants. Shown results were mean relative values ± SEM of 3 independent 725 experiments

Freshly isolated 729 peripheral blood mononuclear cells (PBMC) from asymptomatic (CP-AS, n=8) and hospitalized 730 COVID-19 patients (CP, n=6) as well as matched healthy donors (HD, n=5) were stained with a 731 cocktails of antibodies to study by flow cytometry plasmacytoid dendritic cell (pDC) frequency and 732 absolute number (A), diversification and activation status

The percentage (%) of 735 shown pDC sub-populations

HLADR + gated pDC and depicted for each studied patients or HD together with 737 mean ± SEM values. Surface expression of PD-L1, CD80, CD86 (D) and CXCR4

was determined as mean fluorescence intensity (MFI) and shown results were mean 739 relative values ± SEM of analyzed patients or HD. P-values were depicted as follows: *

Peripheral blood mononuclear cells (PBMC) and sera were collected 744 from asymptomatic (CP-AS, n=8) and hospitalized COVID-19 patients (CP, n=6) as well as 745 matched healthy donors (HD, n=5). (A) Relative expression of Mx1 gene was measured by 746 quantitative real time PCR analysis and normalized to TBP level by using the equation 2 -ΔCt in total 747 RNA isolated from ex vivo PBMC. (B) Production of IFN-αs was tested in serum samples by a 748 specific ELISA kit. Production of cytokines (IL-6, TNF-α, IL-1β, IL-10) (C) and chemokines 749 (CXCL-10, CCL-2, CXCL-8) (D) was tested by multiparametric cytokine bead arrays in collected 750 serum samples

Kinetic of expression of cytokine and chemokine in PBMC stimulated by SARS-CoV-755 2. Peripheral blood mononuclear cells (PBMC) were left untreated (not stimulated, ns) or stimulated 756 for 24 or 48 hours with SARS-CoV-2 (MOI=0.04 and MOI=0.1) (A, B) Production of cytokine IL-757 6 (A) and chemokines CXCL-10 and CXCL-9 (B) was tested by multiparametric cytokine bead 758 arrays in collected cell culture supernatants. Shown results were mean relative values ± SEM of 3 759 independent experiments

Analysis of SARS-CoV-2 entry factors in pDC and 761 monocytes and cytokine production in isolated CD14+ monocytes

B) pDC, monocytes and Calu-3 cell line were left 764 not stimulated (ns) or stimulated with 1000 U/mL of recombinant IFN-α or IFN-β. Gene expression 765 of ACE-2, TMPRSS2 and Mx1 was measured by quantitative RT-PCR. (C) Monocytes were left 766 untreated (not stimulated, ns) or stimulated for 24 hours with SARS-CoV-2 (MOI=0.04 and 767 MOI=0.1). Production of IFN-αs and IL-6 was tested by specific ELISA in collected cell culture 768 supernatants

Representative gating strategy for pDC phenotypical analysis in COVID-19 patients

CP-AS, n=8) and 771 hospitalized COVID-19 patients (CP, n=6) and matched healthy donors (HD, n=5) were stained 772 with a well-established antibody cocktails to study by flow cytometry plasmacytoid dendritic cell 773 (pDC) diversification and activation status as well as expression of chemokine receptors. (A) The 774 percentage (%) of total pDC was

In pDC we also evaluated the % of PD-L1 or CD80 expressing cells. 776 (B, C) Surface expression of PD-L1, CD80, CD86 (B) and CXCR4, CXCR3, CCR7, CD62-L (C) 777 was determined as mean fluorescence intensity (MFI) in CP or HD gated pDC

Evaluation of cell death in human PBMC cultures treated with live SARS-CoV2

Main demographic and clinical characteristics of hospitalized COVID-19 patients

Main demographic and clinical characteristics of asymptomatic COVID-19 patients

Assay by using the Reed-Muench formula and reported as TCID 50